The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Items 201–300 of 694
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 27
Mortaheb, S., Fort, L. D., Mason, N. L., Mallaroni, P., Ramaekers, J. G., & Athena Demertzi, A. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.04.001 · Cited by 31
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 27
Meade, E., Hehir, S., Rowan, N. J., & Garvey, M. (2022) · Journal of Fungi · doi:10.3390/jof8030290 · Cited by 29
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Kaminski, D., & Reinert, J. P. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205645 · Cited by 27
Bornemann, J. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1761573 · Cited by 24
Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain
Kolbman, N., Liu, T., Guzzo, P. R., Gilligan, J., Mashour, G. A., Vanini, G., & Pal, D. (2023) · Current Biology · doi:10.1016/j.cub.2023.10.016 · Cited by 23
Co-design of Guidance for Patient and Public Involvement in Psychedelic Research
Close, J. B., Bornemann, J., Piggin, M., Jayacodi, S., Luan, L., Carhart-Harris, R. L., & Spriggs, M. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727496 · Cited by 25
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Psychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 32
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023) · Network Neuroscience · doi:10.1162/netn_a_00349 · Cited by 21
Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”
O’Shaughnessy, D. M., & Berlowitz, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.639124 · Cited by 22
Rankaduwa, S., & Owen, A. M. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad001 · Cited by 23
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
Substances of abuse and the blood brain barrier: Interactions with physical exercise
Małkiewicz, M. A., Małecki, A., Toborek, M. J., Szarmach, A., & Winklewski, P. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.026 · Cited by 21
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 28
Šabanović, M., Lazari, A., Blanco-Pozo, M., Tisca, C., Tachrount, M., Martins-Bach, A. B., Lerch, J. P., Walton, M. E., & Bannerman, D. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02439-2 · Cited by 23
Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
Dorsen, C. G., Palamar, J. J., & Shedlin, M. G. (2018) · Addiction Research & Theory · doi:10.1080/16066359.2018.1455187 · Cited by 23
McCulloch, D. E.-W., Olsen, A. S., Ozenne, B., Stenbæk, D. S., Armand, S., Madsen, M. K., Knudsen, G. M., & Fisher, P. M. (2023) · medRxiv · doi:10.1101/2023.07.03.23292164 · Cited by 21
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114940 · Cited by 20
Moreton, S. G., Arena, A. F. A., Foy, Y., & Menzies, R. E. (2023) · Death Studies · doi:10.1080/07481187.2023.2169848 · Cited by 21
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 22
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Richard, J., & Garcia‐Romeu, A. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00629-8 · Cited by 22
Self-citationKervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., Roméo, B., & Benyamina, A. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad078 · Cited by 22
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 25
Effects of Psychedelics in Older Adults: A Prospective Cohort Study
Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Pasquini, L. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.05.007 · Cited by 19
5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?
Bryson, A., Carter, O. L., Norman, T. R., & Kanaan, R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx011 · Cited by 20
Psychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 18
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
Meshkat, S., Malik, G., Zeifman, R. J., Swainson, J., Balachandra, K., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106163 · Cited by 21
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 20
Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 20
Self-citationDeciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111753 · Cited by 18
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Hogea, L., Tabugan, D. C., Costea, I., Albai, O., Nussbaum, L. A., Cojocaru, A., Corsaro, L., & Anghel, T. (2025) · Medicina · doi:10.3390/medicina61020278 · Cited by 19
It’s time to take psilocybin seriously as a possible treatment for substance use disorders
Bogenschutz, M. P. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1200060 · Cited by 18
Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments
Hutchison, C. A., & Bressi, S. (2020) · Clinical Social Work Journal · doi:10.1007/s10615-019-00743-x · Cited by 17
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Corso, S. J. F., O’Malley, K. Y., Subaiya, S., Mayall, D., & Dakwar, E. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.116 · Cited by 20
Schmitz, G. P., Chiu, Y.-T., Foglesong, M. L., Magee, S. N., MacKinnon, M., König, G. M., Kostenis, E., Hsu, L.-M., Shih, Y.-Y. I., Roth, B. L., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03611-0 · Cited by 20
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward
Jaster, A. M., Hadlock, T. M., Buzzi, B., Maltman, J. L., Silva, G. M., Saha, S., Köşeli, E., Pondelick, A. M., Thakur, N., Zhang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64887-w · Cited by 19
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Roméo, B., Fauvel, B., Dejean, S., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2227171 · Cited by 17
Kamilar-Britt, P., Gordis, E. B., & Earleywine, M. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0020 · Cited by 18
Song, H.-B., & Bau, T. (2023) · Journal of Fungi · doi:10.3390/jof9090924 · Cited by 17
Glynos, N. G., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349565 · Cited by 17
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 21
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
Argento, E., Tupper, K. W., & Socias, M. E. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.11.006 · Cited by 17
Cellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 19
Fauvel, B., Kangaslampi, S., Strika-Bruneau, L., Roméo, B., & Piolino, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2059796 · Cited by 36
Uthaug, M. V., Mason, N. L., Havenith, M. N., Vancura, M., & Ramaekers, J. G. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00193 · Cited by 19
Galanter, M. S., White, W. L., Khalsa, J. H., & Hansen, H. (2023) · Journal of Addictive Diseases · doi:10.1080/10550887.2023.2174785 · Cited by 24
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Psychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2020) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.94 · Cited by 16
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 16
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 15
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 16
Singer, B., Meling, D., Hirsch‐Hoffmann, M., Michels, L., Kometer, M., Smigielski, L., Dornbierer, D., Seifritz, E., Vollenweider, F. X., & Scheidegger, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-55726-x · Cited by 20
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 15
Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
Sloshower, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-76720-8_7 · Cited by 16
Murnane, K. S., Güner, O. F., Bowen, J. P., Rambacher, K. M., Moniri, N. H., Murphy, T. J., Daphney, C. M., Oppong‐Damoah, A., & Rice, K. C. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.003 · Cited by 16
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Spitalier, A., & Mendive, F. M. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.23-00005 · Cited by 14
Azevedo, N., da Silva, M. O., & Madeira, L. (2023) · Philosophies · doi:10.3390/philosophies8050076 · Cited by 15
Psychedelics, epilepsy, and seizures: a review
Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326815 · Cited by 14
Downey, A. E., Chaphekar, A. V., Woolley, J. D., & Raymond‐Flesch, M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01005-z · Cited by 15
Effinger, D. P., Hoffman, J. L., Mott, S., Magee, S. N., Quadir, S. G., Rollison, C. S., Toedt, D., Sanchez, M. E., High, M. W., Hodge, C. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49741-9 · Cited by 16
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Vamvakopoulou, I. A., & Nutt, D. J. (2024) · European Addiction Research · doi:10.1159/000540062 · Cited by 18
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 16
Psilocybin for depression: Considerations for clinical trial design
O’Donnell, K. C., Mennenga, S. E., & Bogenschutz, M. P. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.026 · Cited by 18
Posttraumatic Stress Disorder After a Psychedelic Experience, a Case Report
Rubin-Kahana, D. S., Hassan, A. N., & Foll, B. L. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000734 · Cited by 14
Gabbard’s Textbook of Psychotherapeutic Treatments
Crisp-Han, H., & Gabbard, G. O. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233 · Cited by 17
Lessons to be learned from early psychedelic therapy in Denmark
Erritzøe, D., & Richards, W. A. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1336252 · Cited by 14
Pontual, A. A. D. D., Tófoli, L. F., Collares, C. F., Ramaekers, J. G., & Corradi-Webster, C. M. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.679016 · Cited by 15
McCulloch, D., Knudsen, G., Barrett, F., Doss, M. K., Carhart-Harris, R. L., Rosas, F., Deco, G., Kringelbach, M., Preller, K., Ramaekers, J., et al. (2021) · Neuroscience and Biobehavioral Reviews · doi:10.31234/osf.io/64kyg · Cited by 106
Schmitz, G. P., Chiu, Y.-T., König, G. M., Kostenis, E., Roth, B. L., & Herman, M. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.15.516655 · Cited by 16
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Brouns, E. J., Ekins, T. G., & Ahmed, O. J. (2025) · Psychedelics. · doi:10.61373/pp025r.0002 · Cited by 13
Psilocybin or Nicotine Patch for Smoking Cessation
Johnson, M. W., Naudé, G. P., Hendricks, P. S., & Garcia‐Romeu, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0972 · Cited by 14
Self-citationArmstrong, S. B., Levin, A. W., Xin, Y., Horan, J., Luoma, J. B., Nagib, P. B., Pilecki, B. C., & Davis, A. K. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00245 · Cited by 13
Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13
Natural products as the therapeutic strategies for addiction
Yu, R., Kong, D., Liao, C., Yu, Y., He, Z., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116687 · Cited by 13
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”
Bornemann, J., Close, J. B., Ahmad, K., Barba, T., Godfrey, K., Macdonald, L., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1320780 · Cited by 15
Rose, J. R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00363 · Cited by 17
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Jacobs, E. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00128 · Cited by 17
Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands
Lutkajtis, A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00162 · Cited by 15
Earleywine, M., Mian, M. N., Altman, B. R., & Leo, J. A. D. (2022) · Cannabis · doi:10.26828/cannabis/2022.02.02 · Cited by 12
Yaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., & Garcia‐Romeu, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106998 · Cited by 13
Self-citationMason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2020) · Drug Science Policy and Law · doi:10.1177/2050324519900068 · Cited by 15
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Self-citationKunicki, Z. J., Hallgren, M. Å., Uebelacker, L. A., Brown, R. A., Price, L. H., & Abrantes, A. M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107156 · Cited by 12
Christianity and Psychedelic Medicine: A Pastoral Approach
McCarthy, B. C. (2022) · Christian bioethics Non-Ecumenical Studies in Medical Morality · doi:10.1093/cb/cbac008 · Cited by 14
Carlisle, N. A., Dourron, H. M., MacCarthy, S., Zarrabi, A. J., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0018 · Cited by 15
Spending Time in Nature: The Overlooked Health Behavior
Maddock, J. E., & Johnson, S. S. (2023) · American Journal of Health Promotion · doi:10.1177/08901171231210806 · Cited by 16
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
McCulloch, D. E.-W., Liechti, M. E., Kuypers, K. P. C., Nutt, D., Lundberg, J., Stenbæk, D. S., Goodwin, G. M., Gründer, G., Butlen‐Ducuing, F., Haberkamp, M., et al. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.103938 · Cited by 14
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 16
Psychedelics as a potential treatment for tobacco use disorder: a systematic review
Spoelstra, S. K., Schoevers, R. A., Venema, S. D., & Knegtering, H. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00095-0 · Cited by 12
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
